Fatty acids and selected endocannabinoids content in cerebrospinal fluids from patients with neuroinfections.
Cerebrospinal fluid
Endocannabinoids
Fatty acids
Inflammation
Neuroinfections
Pathogenesis
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
25
09
2018
accepted:
15
11
2018
pubmed:
7
12
2018
medline:
7
6
2019
entrez:
7
12
2018
Statut:
ppublish
Résumé
Neuroinfections are a significant medical problem and can have serious health consequences for patients. Their outcome, if not fatal, can be associated with permanent residual deficits. Cerebrospinal fluid (CSF) examination is commonly used for meningitis confirmation. Fatty acids (FA) are precursors of lipid mediators with pharmacological activity. They actively modulate inflammation as well as contribute to its resolution. Therefore the aim of this study was to determine the FA and selected endocannabinoids (ECB) content in the CSF obtained from patients with bacterial (BM) and viral meningitis (VM) using chromatographic techniques. A significantly lower level of saturated FA was found in patients with BM and VM as compared to controls. There was a significantly higher concentration of long-chain monounsaturated FA and polyunsaturated n-6 FA in the CSF obtained from patients with neuroinfection. Moreover, a significant reduction of n-3 FA in CSF obtained from patients with BM and VM was demonstrated. The highest amount of ECB was detected in the CSF of patients with VM: eicosapentaenoyl ethanolamide (1.65 pg/mL), docosahexaenoyl ethanolamide (655.5 pg/mL) and nervonoyl ethanolamide (3.09 ng/mL). Results indicate the participation of long-chain monounsaturated and polyunsaturated FA and their derivatives in the inflammatory process and likely in the process of resolution of inflammation during neuroinfection. It seems that the determination of the FA and ECB profile in CSF may be a valuable biomarker of health and may allow the development of new pharmacological strategies, therapeutic goals and fatty acids supplementation necessary in the fight against inflammation of the central nervous system.
Identifiants
pubmed: 30519835
doi: 10.1007/s11011-018-0347-7
pii: 10.1007/s11011-018-0347-7
pmc: PMC6351517
doi:
Substances chimiques
Biomarkers
0
Endocannabinoids
0
Fatty Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-339Références
Toxicol Lett. 2016 Sep 6;258:93-100
pubmed: 27329536
Neurochem Res. 2000 Feb;25(2):269-76
pubmed: 10786712
Brain Behav Immun. 2015 Jan;43:1-8
pubmed: 25451610
Chem Phys Lipids. 2008 May;153(1):24-33
pubmed: 18346461
Curr Med Chem. 2016;23(8):816-31
pubmed: 26795198
Metab Brain Dis. 2018 Aug;33(4):1141-1153
pubmed: 29569150
Brain Behav Immun. 2011 Jul;25(5):872-82
pubmed: 20854895
J Neurochem. 1987 Feb;48(2):503-9
pubmed: 3794719
Neurosci Lett. 2003 Oct 2;349(2):136-8
pubmed: 12946571
Histol Histopathol. 2004 Apr;19(2):535-64
pubmed: 15024715
Chem Rev. 2011 Oct 12;111(10):5922-43
pubmed: 21766791
Brain Res. 2003 Sep 26;985(2):198-201
pubmed: 12967724
Folia Biol (Krakow). 2016;64(1):3-10
pubmed: 27172707
Chem Phys Lipids. 2003 Nov;126(1):1-27
pubmed: 14580707
Biochim Biophys Acta. 2009 Apr;1788(4):842-57
pubmed: 19061857
Neurochem Int. 2009 Mar-Apr;54(3-4):253-63
pubmed: 19111869
Infect Immun. 1997 Dec;65(12):5074-81
pubmed: 9393798
J Nutr. 2009 Jan;139(1):82-9
pubmed: 19056659
J Neurochem. 1985 Jul;45(1):168-72
pubmed: 2987409
Neurochem Res. 2001 Dec;26(12):1265-70
pubmed: 11885776
Eur J Pharmacol. 2016 Aug 15;785:77-86
pubmed: 27083549
Neurotherapeutics. 2016 Jul;13(3):562-70
pubmed: 27365085
Neurobiol Dis. 2004 Jun;16(1):1-13
pubmed: 15207256
Adv Biol Regul. 2014 Jan;54:99-110
pubmed: 24113376
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6034-E6043
pubmed: 28687674
Infect Immun. 2001 Feb;69(2):845-52
pubmed: 11159977
Pharmacol Rep. 2016 Apr;68(2):319-28
pubmed: 26922534
J Neurosurg. 1980 Sep;53(3):323-31
pubmed: 7420147
J Infect Dis. 1992 Aug;166(2):350-8
pubmed: 1634806
Future Microbiol. 2012 Mar;7(3):383-94
pubmed: 22393891
Nat Rev Microbiol. 2011 Jun;9(6):427-39
pubmed: 21522191
Ann Nutr Metab. 2016;69 Suppl 1:7-21
pubmed: 27842299
J Clin Invest. 2003 Sep;112(5):736-44
pubmed: 12952922
Mol Microbiol. 2010 Jul;77(2):431-43
pubmed: 20497331